|
Orthologous residues
|
|
PSTPIP1 (human): Y345‑p, PSTPIP1 (mouse): Y344‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], HER14 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
PDGF
|
|
|
|
increase
|
|
|
EGF
|
|
|
|
increase
|
|
|
PP2
|
EGF
|
|
|
no effect upon treatment-induced increase
|
|
|
vanadate
|
|
|
|
increase
|
|
|
insulin
|
|
|
|
no change compared to control
|
|
|
